Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102803 · ClinicalTrials.gov registry record · Phase 3
D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
A Phase 3 study, sponsored by Southern Methodist University.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT01102803: Completed Phase 3 study, sponsored by Southern Methodist University.
NCT01102803 is a Phase 3 study that has completed, run by Southern Methodist University. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01102803, a Phase 3 study, has completed, sponsored by Southern Methodist University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
Primary Outcome
Self-report measure that assesses fear and avoidance of a variety of heights situations. This questionnaire (Cohen, 1977) describes 20 situations and assesses levels of avoidance (0-3) and anxiety (0-6). These scales widely used measure of acrophobia with adequate retest reliability (r = .82-.86) and validity (Baker et al., 1973). Higher scores indicate higher levels of avoidance/anxiety (i.e., worse outcome). All subscales are summed for a total score. AAVQ will be assessed at each visit throug
Interventions
- DRUG Placebo
- DRUG D-Cycloserine
- BEHAVIORAL Individual Cognitive Behavioral Therapy (CBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT01102803 record still lists
NCT01102803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01102803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01102803 about?
NCT01102803 is a clinical study titled "D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia". The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
What is the current status of trial NCT01102803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2010-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01102803?
The interventions under investigation include: Placebo (DRUG), D-Cycloserine (DRUG), Individual Cognitive Behavioral Therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01102803?
This trial is sponsored by Southern Methodist University, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01102803's enrollment target sits among peer trials
40 1878th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia